FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034276737> ?p ?o ?g. }

• W2034276737 endingPage "471" @default.
• W2034276737 startingPage "459" @default.
• W2034276737 abstract "Pulmonary arterial hypertension (PAH) is associated with poor prognosis despite significant recent advances in its treatment. An intravenous formulation of epoprostenol sodium containing glycine and mannitol (epoprostenol GM; GlaxoSmithKline, London, UK) is widely used to treat PAH. A new formulation of epoprostenol sodium containing arginine and sucrose excipients (epoprostenol AS; Actelion Pharmaceuticals Japan Ltd., Tokyo, Japan) shows better stability at room temperature after preparing diluted solutions. The primary objective of this study was to evaluate the safety and tolerability of switching from epoprostenol GM to epoprostenol AS in Japanese patients with PAH. The authors also evaluated the efficacy and treatment satisfaction after switching formulations. This was a two-site, open-label, single-arm, Phase 3b study. Eight adult Japanese PAH patients (seven females) treated with a stable dose of epoprostenol GM for ≥30 days were switched to epoprostenol AS and followed for 12 weeks. Outcomes included safety, changes from baseline to 12 weeks in pulmonary hemodynamic factors (pulmonary vascular resistance, mean pulmonary arterial pressure, and cardiac output), and treatment satisfaction, assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM-9). The mean (range) age and time since diagnosis of PAH were 48 (25–69) years and 6.2 (0.6–13.9) years, respectively. There were no unexpected safety or tolerability concerns after switching formulations. The epoprostenol dose was maintained after switching formulations. There were no significant changes in pulmonary hemodynamic factors from baseline to week 12. Regarding treatment satisfaction, there was a significant improvement in convenience, which is demonstrated in the score of the domain increased from 51.40 ± 10.19 at baseline to 58.33 ± 12.96 at week 12 (P < 0.05). Switching from epoprostenol GM to the same dose of epoprostenol AS was well tolerated over 12 weeks of treatment, and pulmonary hemodynamics were maintained. Switching to epoprostenol AS was also associated with improvements in treatment satisfaction (convenience). Clinical Trials: JapicCTI-122017." @default.
• W2034276737 created "2016-06-24" @default.
• W2034276737 creator A5006485588 @default.
• W2034276737 creator A5051561328 @default.
• W2034276737 creator A5069453818 @default.
• W2034276737 creator A5084024849 @default.
• W2034276737 creator A5088700596 @default.
• W2034276737 date "2013-05-01" @default.
• W2034276737 modified "2023-10-08" @default.
• W2034276737 title "Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)" @default.
• W2034276737 cites W1976720943 @default.
• W2034276737 cites W1996985763 @default.
• W2034276737 cites W2012400171 @default.
• W2034276737 cites W2026146833 @default.
• W2034276737 cites W2039172749 @default.
• W2034276737 cites W2054946684 @default.
• W2034276737 cites W2070022895 @default.
• W2034276737 cites W2127994398 @default.
• W2034276737 cites W2127994875 @default.
• W2034276737 cites W2134244631 @default.
• W2034276737 cites W2141132806 @default.
• W2034276737 cites W2142743112 @default.
• W2034276737 cites W2159677723 @default.
• W2034276737 cites W2163438871 @default.
• W2034276737 cites W2313098007 @default.
• W2034276737 cites W2321522617 @default.
• W2034276737 cites W2323812424 @default.
• W2034276737 cites W2614800967 @default.
• W2034276737 cites W4232531997 @default.
• W2034276737 cites W4293178741 @default.
• W2034276737 doi "https://doi.org/10.1007/s12325-013-0029-0" @default.
• W2034276737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3685701" @default.
• W2034276737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23653230" @default.
• W2034276737 hasPublicationYear "2013" @default.
• W2034276737 type Work @default.
• W2034276737 sameAs 2034276737 @default.
• W2034276737 citedByCount "12" @default.
• W2034276737 countsByYear W20342767372014 @default.
• W2034276737 countsByYear W20342767372015 @default.
• W2034276737 countsByYear W20342767372016 @default.
• W2034276737 countsByYear W20342767372017 @default.
• W2034276737 countsByYear W20342767372018 @default.
• W2034276737 countsByYear W20342767372021 @default.
• W2034276737 countsByYear W20342767372022 @default.
• W2034276737 countsByYear W20342767372023 @default.
• W2034276737 crossrefType "journal-article" @default.
• W2034276737 hasAuthorship W2034276737A5006485588 @default.
• W2034276737 hasAuthorship W2034276737A5051561328 @default.
• W2034276737 hasAuthorship W2034276737A5069453818 @default.
• W2034276737 hasAuthorship W2034276737A5084024849 @default.
• W2034276737 hasAuthorship W2034276737A5088700596 @default.
• W2034276737 hasBestOaLocation W20342767371 @default.
• W2034276737 hasConcept C126322002 @default.
• W2034276737 hasConcept C164705383 @default.
• W2034276737 hasConcept C178853913 @default.
• W2034276737 hasConcept C197934379 @default.
• W2034276737 hasConcept C2778375690 @default.
• W2034276737 hasConcept C2780930700 @default.
• W2034276737 hasConcept C42219234 @default.
• W2034276737 hasConcept C71924100 @default.
• W2034276737 hasConceptScore W2034276737C126322002 @default.
• W2034276737 hasConceptScore W2034276737C164705383 @default.
• W2034276737 hasConceptScore W2034276737C178853913 @default.
• W2034276737 hasConceptScore W2034276737C197934379 @default.
• W2034276737 hasConceptScore W2034276737C2778375690 @default.
• W2034276737 hasConceptScore W2034276737C2780930700 @default.
• W2034276737 hasConceptScore W2034276737C42219234 @default.
• W2034276737 hasConceptScore W2034276737C71924100 @default.
• W2034276737 hasIssue "5" @default.
• W2034276737 hasLocation W20342767371 @default.
• W2034276737 hasLocation W20342767372 @default.
• W2034276737 hasLocation W20342767373 @default.
• W2034276737 hasLocation W20342767374 @default.
• W2034276737 hasOpenAccess W2034276737 @default.
• W2034276737 hasPrimaryLocation W20342767371 @default.
• W2034276737 hasRelatedWork W1556562895 @default.
• W2034276737 hasRelatedWork W2046069863 @default.
• W2034276737 hasRelatedWork W2057339290 @default.
• W2034276737 hasRelatedWork W2087016115 @default.
• W2034276737 hasRelatedWork W2160729253 @default.
• W2034276737 hasRelatedWork W2335774562 @default.
• W2034276737 hasRelatedWork W2349164817 @default.
• W2034276737 hasRelatedWork W2363981502 @default.
• W2034276737 hasRelatedWork W3189762672 @default.
• W2034276737 hasRelatedWork W4251165208 @default.
• W2034276737 hasVolume "30" @default.
• W2034276737 isParatext "false" @default.
• W2034276737 isRetracted "false" @default.
• W2034276737 magId "2034276737" @default.
• W2034276737 workType "article" @default.